tetano
Editor, Senior Moderator
Vet Microbiol
. 2021 May 8;258:109106.
doi: 10.1016/j.vetmic.2021.109106. Online ahead of print.
H7N9 influenza virus-like particle based on BEVS protects chickens from lethal challenge with highly pathogenic H7N9 avian influenza virus
Jun Li[SUP] 1 [/SUP], Rumeng Li[SUP] 1 [/SUP], Qi Zhang[SUP] 1 [/SUP], Peipei Peng[SUP] 1 [/SUP], Xiaoquan Wang[SUP] 1 [/SUP], Min Gu[SUP] 1 [/SUP], Zenglei Hu[SUP] 1 [/SUP], Xinan Jiao[SUP] 2 [/SUP], Daxin Peng[SUP] 1 [/SUP], Jiao Hu[SUP] 3 [/SUP], Xiufan Liu[SUP] 1 [/SUP]
Affiliations
Abstract
H7N9 avian influenza virus poses a dual threat to both poultry industry and public health. Therefore, it is highly urgent to develop an effective vaccine to reduce its pandemic potential. Virus-like particles (VLP) represent an effective approach for pandemic vaccine development. In this study, a recombinant baculovirus co-expressing the HA, NA and M1 genes of the H7N9 virus was constructed for generation of H7N9 VLP. Single immunization of chickens with 15 ?g of the VLP or the commercial whole virus inactivated vaccine stimulates high hemagglutination inhibition, virus neutralizing and HA-specific IgY antibodies. Moreover, the antiserum had a good cross-reactivity with H7N9 field strains isolated in different years. Within 14 days after a lethal challenge with highly pathogenic (HP) H7N9 virus, no clinical symptoms and death were observed in the vaccinated chickens, and no virus was recovered from the organs. Compared to the non-vaccinated chickens, H7N9 VLP significantly reduced the proportion of animals shedding virus. Only 30 % of the VLP-vaccinated birds shed virus, whereas virus shedding was detected in 50 % of the chickens immunized with the commercial vaccine. Moreover, both vaccines dramatically alleviated pulmonary lesions caused by HP H7N9 virus, with a greater degree observed for the VLP. Altogether, our results indicated that the H7N9 VLP vaccine candidate confers a complete clinical protection against a lethal challenge with HP H7N9 virus, significantly inhibits virus shedding and abolishes viral replication in chickens. The VLP generated in this study represents a promising alternative strategy for the development of novel H7N9 avian influenza vaccines for chickens.
Keywords: Chicken; H7N9 influenza virus; Recombinant baculovirus; Sf9 cells; Vaccine; Virus-like particles.
. 2021 May 8;258:109106.
doi: 10.1016/j.vetmic.2021.109106. Online ahead of print.
H7N9 influenza virus-like particle based on BEVS protects chickens from lethal challenge with highly pathogenic H7N9 avian influenza virus
Jun Li[SUP] 1 [/SUP], Rumeng Li[SUP] 1 [/SUP], Qi Zhang[SUP] 1 [/SUP], Peipei Peng[SUP] 1 [/SUP], Xiaoquan Wang[SUP] 1 [/SUP], Min Gu[SUP] 1 [/SUP], Zenglei Hu[SUP] 1 [/SUP], Xinan Jiao[SUP] 2 [/SUP], Daxin Peng[SUP] 1 [/SUP], Jiao Hu[SUP] 3 [/SUP], Xiufan Liu[SUP] 1 [/SUP]
Affiliations
- PMID: 34004568
- DOI: 10.1016/j.vetmic.2021.109106
Abstract
H7N9 avian influenza virus poses a dual threat to both poultry industry and public health. Therefore, it is highly urgent to develop an effective vaccine to reduce its pandemic potential. Virus-like particles (VLP) represent an effective approach for pandemic vaccine development. In this study, a recombinant baculovirus co-expressing the HA, NA and M1 genes of the H7N9 virus was constructed for generation of H7N9 VLP. Single immunization of chickens with 15 ?g of the VLP or the commercial whole virus inactivated vaccine stimulates high hemagglutination inhibition, virus neutralizing and HA-specific IgY antibodies. Moreover, the antiserum had a good cross-reactivity with H7N9 field strains isolated in different years. Within 14 days after a lethal challenge with highly pathogenic (HP) H7N9 virus, no clinical symptoms and death were observed in the vaccinated chickens, and no virus was recovered from the organs. Compared to the non-vaccinated chickens, H7N9 VLP significantly reduced the proportion of animals shedding virus. Only 30 % of the VLP-vaccinated birds shed virus, whereas virus shedding was detected in 50 % of the chickens immunized with the commercial vaccine. Moreover, both vaccines dramatically alleviated pulmonary lesions caused by HP H7N9 virus, with a greater degree observed for the VLP. Altogether, our results indicated that the H7N9 VLP vaccine candidate confers a complete clinical protection against a lethal challenge with HP H7N9 virus, significantly inhibits virus shedding and abolishes viral replication in chickens. The VLP generated in this study represents a promising alternative strategy for the development of novel H7N9 avian influenza vaccines for chickens.
Keywords: Chicken; H7N9 influenza virus; Recombinant baculovirus; Sf9 cells; Vaccine; Virus-like particles.